Abstract
Abstract 1238
Poster Board I-260
Regulatory T cells (Treg) are thought to be potent suppressors of anti-tumor immunity and increased Treg frequencies are correlated with poor prognosis in patients suffering from various tumor types. In the current study we analysed Treg (CD3+CD4+CD25+CD127−) in the peripheral blood of 101 previously untreated chronic lymphocytic B-cell leukemia (B-CLL) patients as well as 170 healthy volunteers using flow cytometry. Statistical analysis was used for correlation with clinical data. Treg of B-CLL patients expressed high numbers of FOXP3 and efficiently suppressed T cell proliferation. No significant difference in relative Treg numbers between B-CLL patients and healthy controls could be observed, but Treg numbers showed a significant negative correlation with time to initial treatment. Defining a cut-off of 9.75%, patients with higher Treg showed significantly shorter time to initial treatment (median 4.4 yr, 95% CI 2.2 – 6.6 yr) when compared to the lower Treg group (median not reached at 4.25 yr) (logrank P=0.001). Further subdivision of patients into quartiles according to Treg numbers showed a clear dose-dependency (logrank P=0.027). Treg numbers had significant prognostic power for time to initial treatment in univariate (P=0.001) as well as multivariate (P=0.037) Cox-regression analysis including Rai stage, IgVH mutational status, chromosomal aberrations and CD38 expression. In conclusion, higher Treg numbers are significantly and independently correlated with shorter time to initial treatment in B-CLL in a dose-dependent fashion and show significant prognostic power for time to initial treatment. These results provide evidence for the role of Treg in the clinical course of B-CLL.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal